Which hedge funds own GMED? GLOBUS MED INC, Q2 2026 13F holders
Healthcare · Open on the interactive board
10 of the hedge funds tracked by WhaleCreep disclosed a position in GMED (GLOBUS MED INC) in their Q2 2026 13F filings, worth $362.7m in total. The largest holder by portfolio weight is Sculptor Capital Management at 2.5% of its book. 1 manager opened a new position this quarter: Renaissance Technologies LLC. 3 exited: Ancora Advisors, Farallon Capital Management, Maverick Capital.
10tracked managers holding
1opened this quarter
3exited this quarter
Which hedge funds hold GMED? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Sculptor Capital Management | Q2 2026 | 2.5% | $237.0m | 3,000,000 | -2% | reduced |
| Bridgewater Associates | Q2 2026 | 0.1% | $27.8m | 351,974 | 7% | added |
| Holocene Advisors | Q2 2026 | 0.1% | $31.6m | 399,932 | -48% | reduced |
| Woodline Partners | Q2 2026 | 0.1% | $17.9m | 226,640 | 231% | added |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $1.5m | 19,565 | 369% | added |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $15.6m | 196,918 | – | new |
| WCM Investment Management | Q2 2026 | 0.0% | $13.5m | 160,304 | -21% | reduced |
| Marshall Wace | Q2 2026 | 0.0% | $14.9m | 188,541 | -66% | reduced |
| Millennium Management | Q2 2026 | 0.0% | $2.3m | 28,835 | -98% | reduced |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $655.8k | 8,300 | -71% | reduced |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Ancora Advisors | 0.0% | $24.2k |
| Farallon Capital Management | 0.0% | $344.6k |
| Maverick Capital | 0.1% | $1.3m |
Held in a manager's last filing on record
These managers have not filed for the latest quarter; their last disclosure is dated.
| Manager | Last filing | Weight |
|---|---|---|
| Bares Capital Management | Q3 2025 | 2.8% |
How has hedge fund ownership of GMED changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 10 | $362.7m |
| Q1 2026 | 13 | $745.5m |
| Q4 2025 | 4 | $25.9m |
| Q3 2025 | 6 | $77.2m |
| Q2 2025 | 4 | $50.3m |
| Q1 2025 | 5 | $69.0m |
| Q4 2024 | 3 | $58.0m |
| Q3 2024 | 5 | $35.2m |
| Q2 2024 | 5 | $24.1m |
| Q1 2024 | 4 | $13.7m |
| Q4 2023 | 3 | $13.2m |
| Q3 2023 | 5 | $19.6m |
| Q2 2023 | 6 | $75.1m |
| Q1 2023 | 7 | $9.8m |
| Q4 2022 | 4 | $8.3m |
| Q3 2022 | 3 | $11.1m |
Counts every tracked manager that disclosed GMED in that quarter's filing, including managers that have since stopped filing.